Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma

Clinical Laboratory

Volumn 57, Issue 11-12, 2011, Pages 879-885

  Lin, Wei ^a,b   Chen, Yan Ling ^a   Jiang, Lei ^a   Chen, Jin Kun ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b PUTIAN UNIVERSITY   (China)

Author keywords

Chemerin; Dendritic cells; Hepatocellular carcinoma; Natural killer cells

Indexed keywords

CHEMERIN PROTEIN; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SURVIVAL; CELL INFILTRATION; DENDRITIC CELL; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MALE; NATURAL KILLER CELL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOKINES; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SAMPLING STUDIES;

EID: 83455244583     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010;16:133-44.
2. Kollmar O, Rupertus K, Scheuer C, et al. CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. Int J Cancer 2010;126:1302-15.
3. Johnson EL, Singh R, Singh S, et al. CCL25-CCR9 interaction modulates ovarian cancer cell migration, metalloproteinase expression, and invasion. World J Surg Oncol 2010;8:62.
4. Guo J, Wang B, Zhang M, et al. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity. Gene Ther 2002;9:793-803. (Pubitemid 34679307)
5. Middel P, Brauneck S, Meyer W, Radzun HJ. Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma. BMC Cancer 2010;10:578.
6. Lai HC, Hsiao JR, Chen CW, et al. Endogenous latent membrane protein 1 in Epstein-Barr virus-infected nasopharyngeal carcinoma cells attracts T lymphocytes through upregulation of multiple chemokines. Virology 2010;405:464-73.
7. Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109:3625-32. (Pubitemid 46641708)
8. Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007;282:28175-88. (Pubitemid 47529521)
9. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:217-21.
10. Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009;94:3085-8.
11. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010;72:342-8.
12. Skrzeczyńska-Moncznik J, Stefańska A, Zabel BA, Kapińska-Mrowiecka M, Butcher EC, Cichy J. Chemerin and the recruitment of NK cells to diseased skin. Acta Biochim Pol 2009;56:355-60.
13. Roh SG, Song SH, Choi KC, et al. Chemerin-a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun 2007;362:1013-8.
14. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Semin Cancer Biol 2004;14:209-18. (Pubitemid 38586747)
15. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008;8:243-57. (Pubitemid 351385915)
16. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-14.
17. Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005;174:5490-8. (Pubitemid 40593189)
18. Samson M, Edinger AL, Stordeur P, et al. ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol 1998;28:1689-700. (Pubitemid 28221174)
19. Vermi W, Riboldi E, Wittamer V, et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med 2005;201:509-15. (Pubitemid 40289541)
20. Parolini S, Santoro A, Marcenaro E, et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 2007;109:3625-32. (Pubitemid 46641708)
21. Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med 2009;206:249-58.
22. Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009;249:799-805.
23. Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol 2008;39:1777-83.
24. Larmonier N, Fraszczak J, Lakomy D, Bonnotte B, Katsanis E. Killer dendritic cells and their potential for cancer immunotherapy. Cancer Immunol Immunother 2010;59:1-11.
25. Malmberg KJ, Bryceson YT, Carlsten M, et al. NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy. Cancer Immunol Immunother 2008;57:1541-52.
26. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61. (Pubitemid 37328903)
27. Molling JW, Moreno M, van der Vliet HJ, et al. Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 2008;129:182-94.